Cox regression models for cGVHD and mortality among patients with cGVHD
| Parameter . | Unadjusted models . | Adjusted models . |
|---|---|---|
| NIH chronic GVHD | ||
| HCT date | HR, 0.73; 95% CI, 0.69-0.78; P < .0001 | HR, 0.81; 95% 0.75-0.87; P < .0001 |
| Overall mortality after cGVHD | - | - |
| HCT date | HR, 0.94; 95% CI, 0.83-1.07; P = .375 | HR, 0.88; 95% CI, 0.76-1.01; P = .067 |
| Parameter . | Unadjusted models . | Adjusted models . |
|---|---|---|
| NIH chronic GVHD | ||
| HCT date | HR, 0.73; 95% CI, 0.69-0.78; P < .0001 | HR, 0.81; 95% 0.75-0.87; P < .0001 |
| Overall mortality after cGVHD | - | - |
| HCT date | HR, 0.94; 95% CI, 0.83-1.07; P = .375 | HR, 0.88; 95% CI, 0.76-1.01; P = .067 |
HCT dates were modeled as continuous linear variables, and HR presented in terms of 5-year increments for date of transplantation. Multivariable models were adjusted for recipient age, donor/stem-cell source, patient/donor sex, patient/donor CMV serostatus, the severity of disease (low vs intermediate vs high), TBI dose (modeled as a continuous linear variable), conditioning intensity (NMA vs reduced intensity vs ablative), self-reported race, and GVHD prophylaxis.